- Neratinib intermediate crystal as well as preparation method and application thereof
-
The invention relates to a neratinib intermediate crystal as well as a preparation method and application thereof. The invention especially relates to a crystal form II of an intermediate A compound 6-amino-4-(3-chloro-4-(pyridine-2-substituted methoxy) aniline)-7-ethoxyquinoline carbonitrile. The crystal form II comprises diffraction peaks with diffraction angles 2 theta of 6.3 degrees, 7.8 degrees, 14.0 degrees, 15.1 degrees, 17.1 degrees, 18.8 degrees, 21.5 degrees, 22.2 degrees, 23.4 degrees and 27.5 degrees in an XRPD spectrum. When the intermediate crystal form II is used for preparing the neratinib, the dosage of a solvent can be remarkably reduced, the reaction time is shortened, the yield is increased, and meanwhile, the residual quantity of the intermediate A in a final product is remarkably reduced.
- -
-
Paragraph 0088-0099
(2021/04/21)
-
- Preparation method of neratinib
-
The invention relates to a preparation method of neratinib. The preparation method specifically comprises the steps: (1) in an organic solvent 1, trans-4-dimethylaminocrotonic acid hydrochloride and achloride agent react, and thus a solution containing (e)-4-(dimethylamino)but-2-enoyl chloride (hydrochloride) is obtained; (2) a solution of an organic solvent 2 containing 6-amino-4-[[3-chloro-4-[(pyridine-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinoline is added into the solution obtained in the step (1) to react, and then neratinib hydrochloride is obtained; and (3) the neratinib hydrochloride obtained in the step (2) is mixed with water and an organic solvent 3, a reaction is carried out after the pH value is regulated to be 7-10, and then the neratinib is obtained. The synthesis method has the advantages that the yield is high, the product purity is high, the production cost is low, operation is safe, easy and convenient, and large-scale industrial production is easy.
- -
-
Page/Page column 10-11
(2019/11/04)
-
- SOLID STATE FORMS OF NERATINIB AND SALTS THEREOF
-
Solid state forms of Neratinib and salts thereof, processes for preparation thereof and pharmaceutical compositions thereof are disclosed.
- -
-
Paragraph 0076
(2018/02/28)
-
- Crystal forms and preparation method of neratinib free alkali
-
The invention relates to crystal forms and a preparation method of neratinib free alkali. Specifically, the invention discloses new crystal forms of a compound shown in a formula (I) or a solvate thereof, namely a crystal form III, a crystal form IV, a crystal form V and a crystal form VI respectively. The new crystal forms disclosed by the invention are beneficial to separation and purification of a compound free alkali shown in the formula (I), and process efficiency and chemical quality of a product are greatly improved. (The formula (I) is as shown in the description.).
- -
-
Paragraph 0148; 0149
(2018/09/08)
-
- A to that of the preparation method of the Buddhist
-
The invention relates to the field of pharmaceuticals, in particular to a preparation method of neratinib. The preparation method specifically includes: successively condensing 6-[(E)-4-(dimethylamino)-2-butenamido]-7-ethoxy-4-chloro-3-cyanoquinoline (I) with 2-chloro-4-aminophenol (II) and 2-(chloromethyl)pyridine hydrochloride (III) through an intermediate (E)-N-{4-[3-chloro-4-hydroxyanilino]3-cyano-7-ethoxy-6-quinoline}-4-dimethylamino-2-butenamide (IV). The materials in the preparation method are easy to obtain, and the preparation method is simple, green and economical and has greatly worthy of application.
- -
-
Paragraph 0033-0057
(2017/10/06)
-
- Method for preparing Neratinib
-
The invention relates to a preparation method for neratinib. Specifically, N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-2-diethyl phosphate-acetamide reacts with 2,2-diethoxy-N,N-dimethylethylamine or 2-(dimethylamino)acetaldehyde in the presence of a lithium salt and an alkali to produce neratinib. The method provided by the invention has the advantages of high yield, mild reaction conditions, usage of common and commercially available reagents, a low price, suitability for industrial production and good economic prospects.
- -
-
Paragraph 0031; 0033
(2017/04/03)
-
- Preparation method of antineoplastic drug maleic acid neratinib
-
The invention provides a preparation method of antineoplastic drug maleic acid neratinib. The defects in the prior art are overcome. The preparation method comprises the steps that the formula II and the formula III are coupled to form the formula IV under the effect of a catalyst; a nitro-compound IV is reduced under the effect of a reduction system to form a formula V; an amino compound V and a formula VI are condensed to obtain neratinib VII, and then the neratinib VII and maleic acid form a salt to obtain the maleic acid neratinib I. By the adoption of the technical route, the preparation method has the advantages that the synthetic route is short, reaction conditions are mild, the yield is high, raw materials are wide in source, and environmental protection is achieved.
- -
-
Paragraph 0052; 0053
(2016/10/08)
-
- Method for purifying neratinib
-
The invention relates to a method for purifying neratinib. The method provided by the invention is capable of effectively reducing the content of impurities in neratinib and preparing high-purity neratinib, and moreover is simple in operation, high in yield and very applicable to industrial production.
- -
-
Paragraph 0032; 0034-0035
(2017/04/14)
-
- The Wittig-Horner reaction for the synthesis of neratinib
-
The Wittig-Horner reaction is a classic method to get alkenes by reaction phosphonates with carbonyl compounds. In this study, it was used for the synthesis of the anticancer drug neratinib. In this method, ethyl diethoxyphosphinylacetate and dimethylaminoacetaldehyde diethylacetal, replacing (E)-4-(dimethylamino)but-2-enoyl acid hydrochloride and oxalyl chloride, were used to synthesize the 6-position side chain of neratinib.
- Gu, Ning,Yang, Jiabin,Wang, Peng,Li, Lushen,Chen, Yang,Ji, Min
-
p. 3105 - 3110
(2013/09/23)
-
- IMPROVED PROCESS FOR PREPARATION OF COUPLED PRODUCTS FROM 4-AMINO-3-CYANOQUINOLINES USING STABILIZED INTERMEDIATES
-
This invention discloses improved methods for coupling a 4-(amino)-2-butenoyl group to an amino group at the 6- or 7-position of a 4-amino-3-quinolinecarbonitrile by generating a stabilized 4-(amino)-2-butenoyl chloride hydrochloride.
- -
-
Page/Page column 9-10
(2010/05/13)
-
- Method of preparing 3-cyano-quinolines and intermediates made thereby
-
The present invention relates to methods for preparing substituted 3-cyanoquinolines and intermediates obtained by the methods of the present invention. The methods of the invention comprise reacting an N-aryl-2-propanimide with phosphoryl chloride to produce the substituted 3-cyanoquinolines. The methods further comprise reacting arylamines, orthoformates and active methylenes to produce the N-aryl-2-propenamide.
- -
-
Page/Page column 19
(2010/11/24)
-
- Methods of synthesizing substituted 3-cyanoquinolines and intermediates thereof
-
The invention is directed to methods of making substituted 3-cyanoquinolines, including compounds according to the following formula: The methods are amenable to large scale manufacture, avoid the use of chromatographic separations, and provide stable, high purity product more efficiently than in the prior art.
- -
-
Page/Page column 21
(2008/06/13)
-
- Protein tyrosine kinase enzyme inhibitors
-
This invention provides compounds of formula 1, having the structure wherein R1, R2, R3, R4, and R5 are described within the specification.
- -
-
-
- SUBSTITUTED QUINOLINES AS PROTEIN TYROSINE KINASE ENZYME INHIBITORS
-
This invention provides compounds of formula (I), having the structure wherein R1, R2, R3 are described within the specification. The compounds act as anti-cancer agents by inhibition of HER-2 and EGFR.
- -
-
Page/Page column 13
(2010/02/11)
-
- Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity
-
A series of new 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitrile derivatives that function as irreversible inhibitors of human epidermal growth factor receptor-2 (HER-2) and epidermal growth factor receptor (EGFR) kinases have been prepared. These compounds demonstrated enhanced activities for inhibiting HER-2 kinase and the growth of HER-2 positive cells compared to our EGFR kinase inhibitor 86 (EKB-569). Three synthetic routes were used to prepare these compounds. They were prepared mostly by acylation of 6-amino-4-(arylamino) quinoline-3-carbonitriles with unsaturated acid chlorides or by amination of 4-chloro-6-(crotonamido)-quinoline-3-carbonitriles with monocyclic or bicyclic anilines. The third route was developed to prepare a key intermediate, 6-acetamido-4-chloroquinoline-3-carbonitrile, that involved a safer cyclization step. We show that attaching a large lipophilic group at the para position of the 4-(arylamino) ring results in improved potency for inhibiting HER-2 kinase. We also show the importance of a basic dialkylamino group at the end of the Michael acceptor for activity, due to intramolecular catalysis of the Michael addition. This, along with improved water solubility, resulted in compounds with enhanced biological properties. We present molecular modeling results consistent with the proposed mechanism of inhibition. Binding studies of one compound, 25o (C-14 radiolabeled), showed that it binds irreversibly to HER-2 protein in BT474 cells. Furthermore, it demonstrated excellent oral activity, especially in HER-2 overexpressing xenografts. Compound 25o (HKI-272) was selected for further studies and is currently in phase I clinical trials for the treatment of cancer.
- Tsou, Hwei-Ru,Overbeek-Klumpers, Elsebe G.,Hallett, William A.,Reich, Marvin F.,Floyd, M. Brawner,Johnson, Bernard D.,Michalak, Ronald S.,Nilakantan, Ramaswamy,Discafani, Carolyn,Golas, Jonathan,Rabindran, Sridhar K.,Shen, Ru,Shi, Xiaoqing,Wang, Yu-Fen,Upeslacis, Janis,Wissner, Allan
-
p. 1107 - 1131
(2007/10/03)
-
